Study populations

From September 2013 to June 2014, we prospectively recruited 111 patients with written consent from Union Hospital, Wuhan, Hubei province, China. Approval for the study was got from the Ethics Committee of Tongji Medical College of Huazhong University of Science and Technology. All patients were classified into three groups according to European Society of Cardiology (ESC) guidelines for stable CAD and ACS.^11,12 Patients with either of the following characteristics were excluded: rheumatoid valvular heart disease, malignant arrhythmia cardiogenic shock, known history of malignancies, renal failure, fever of unknown origin, virus hepatitis, immune disorders or receiving immunosuppressive drugs, organ transplantation.